Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:32:49.977Z.
Consensus retrieved: 2026-10-06T15:56:55.835Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:32:49.977Z.
Quote observation: 2026-10-06T18:29:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f5be79ac0e7715def3f298c248b41853c7a510be646acbaec4ce361b11b20d4
Forward PE Ratio (N/A) = Dated Quote Price ($0.82) / Consensus Forward EPS ($-0.46)
FORWARD PE RATIO
N/A
Rein Therapeutics Inc.
Market Cap
$22.88M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $22.88M | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.56M | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.84M | 12.12 |
| Modular Medical, Inc. (MODD)vs › | $21.84M | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.68M | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.99M | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $25.24M | N/A |
| InspireMD, Inc. (NSPR)vs › | $25.30M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.82, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.46 | $-0.46 – $-0.46 | 1 | n/m |
| 2027-12-31 | $-0.47 | $-0.47 – $-0.47 | 1 | n/m |
| 2028-12-31 | $-0.59 | $-0.67 – $-0.52 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
